Research programme: immunomodulatory recombinant fusion proteins - Compugen

Drug Profile

Research programme: immunomodulatory recombinant fusion proteins - Compugen

Alternative Names: BAY 1905254; BAY 1905254/ILDR2; CGEN 15001 based protein therapeutics; CGEN 15001T based protein therapeutics; CGEN 15021 based protein therapeutics; CGEN 15022 based protein therapeutics; CGEN 15031 based protein therapeutics; CGEN 15051 based protein therapeutics; CGEN 15092 based protein therapeutics; CGEN-15029; CGEN-15029 based protein therapeutics; CGEN-15029/PVRIG; CGEN-15029/TIGIT; CGEN-15052 based protein therapeutics; CGEN-15091 based protein therapeutics; COM 701; COM701/PVRIG

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Compugen
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen modulators; CD80 antigen modulators; Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 27 Jul 2018 The US FDA approves IND application for a phase I trial of COM 701 for Solid tumours in USA
  • 02 Jul 2018 The US FDA approves IND application for a phase I trial of BAY 1905254 for Solid tumours
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top